Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECON Study: Celecoxib + Durvalumab + Tremelimumab in Advanced HCC
NCT07174570Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Countries
- 1
- Sponsor
- Emory University
- Modality
- Small Molecules
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of celecoxib oral solution in hepatocellular carcinoma (HCC), sponsored by Emory University. Primary endpoint: Progression-Free Survival up to 2 years. Started Jan 2026; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Treatment (celecoxib, durvalumab, tremelimumab)
Patients receive celecoxib, durvalumab, and tremelimumab.
03
Who it enrols
Adult patients with advanced or metastatic hepatocellular carcinoma, ECOG <= 2, adequate organ function, and completion of prior cancer therapies >= 4 weeks ago. Excludes patients with Child-Pugh score >= 7B, recent ICI therapy within 6 months, or significant cardiovascular disease.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Objective Response Rate
Incidence of Adverse Events
One Treatment Cycle
Incidence of Adverse Events Profile
Beyond the preview
Go deeper on NCT07174570.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174570.